Altimmune Inc (NASDAQ:ALT) — Market Cap & Net Worth
Market Cap & Net Worth: Altimmune Inc (ALT)
Altimmune Inc (NASDAQ:ALT) has a market capitalization of $373.19 Million ($373.19 Million) as of August 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13530 globally and #3293 in its home market, demonstrating a 6.05% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Altimmune Inc's stock price $2.98 by its total outstanding shares 125231517 (125.23 Million). See Altimmune Inc capital spending ratio to understand how much of operating cash flow is reinvested back into capital assets.
Altimmune Inc Market Cap History: 2015 to 2026
Altimmune Inc's market capitalization history from 2015 to 2026. Data shows change from $71.17 Billion to $373.19 Million (-37.73% CAGR).
Index Memberships
Altimmune Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.47 Trillion | 0.02% | #375 of 976 |
|
NASDAQ Composite
IXIC
|
$39.70 Trillion | 0.00% | #1347 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.73 Trillion | 0.02% | #201 of 263 |
Weight: Altimmune Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Altimmune Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Altimmune Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
11026.48x
Altimmune Inc's market cap is 11026.48 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $121.74 Billion | $5.23 Million | $193.85 Million | 23276.72x | 628.01x |
| 2017 | $7.48 Billion | $41.50K | -$46.43 Million | 180139.30x | N/A |
| 2018 | $257.98 Million | $10.33 Million | -$39.17 Million | 24.97x | N/A |
| 2019 | $236.69 Million | $5.80 Million | -$20.52 Million | 40.80x | N/A |
| 2020 | $1.41 Billion | $8.19 Million | -$49.04 Million | 172.58x | N/A |
| 2021 | $1.15 Billion | $4.41 Million | -$97.09 Million | 260.12x | N/A |
| 2022 | $2.06 Billion | $-68.00K | -$84.71 Million | -30294.98x | N/A |
| 2023 | $1.41 Billion | $426.00K | -$88.45 Million | 3307.17x | N/A |
| 2024 | $902.92 Million | $20.00K | -$95.06 Million | 45145.96x | N/A |
| 2025 | $452.09 Million | $41.00K | -$88.09 Million | 11026.48x | N/A |
Competitor Companies of ALT by Market Capitalization
Companies near Altimmune Inc in the global market cap rankings as of August 1, 2026.
Key companies related to Altimmune Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #537 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- Samsung Biologics Co Ltd (KO:207940): Ranked #556 globally with a market cap of $47.90 Billion USD ( ₩70.69 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $481.70 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $738.34 |
| #537 | Argen-X | BR:ARGX | $49.55 Billion | €746.60 |
| #556 | Samsung Biologics Co Ltd | KO:207940 | $47.90 Billion | ₩1527000.00 |
Altimmune Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Altimmune Inc's market cap moved from $71.17 Billion to $ 373.19 Million, with a yearly change of -37.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $373.19 Million | -17.45% |
| 2025 | $452.09 Million | -49.93% |
| 2024 | $902.92 Million | -35.91% |
| 2023 | $1.41 Billion | -31.61% |
| 2022 | $2.06 Billion | +79.59% |
| 2021 | $1.15 Billion | -18.79% |
| 2020 | $1.41 Billion | +496.83% |
| 2019 | $236.69 Million | -8.25% |
| 2018 | $257.98 Million | -96.55% |
| 2017 | $7.48 Billion | -93.86% |
| 2016 | $121.74 Billion | +71.05% |
| 2015 | $71.17 Billion | -- |
End of Day Market Cap According to Different Sources
On Jul 31st, 2026 the market cap of Altimmune Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $373.19 Million USD |
| MoneyControl | $373.19 Million USD |
| MarketWatch | $373.19 Million USD |
| marketcap.company | $373.19 Million USD |
| Reuters | $373.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Altimmune Inc
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.